Dr. Nancy Jean Antonino, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 110 N Main St, Greenville, PA 16125 Phone: 724-588-3001 Fax: 724-588-9620 |
Miss Molly S Smathers, CCC/SLP-L Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 339 E Jamestown Rd, Greenville, PA 16125 Phone: 724-588-7613 |
Mrs. Kelli Marie Alexander, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 339 E Jamestown Rd, Greenville, PA 16125 Phone: 724-588-7613 |
Theresa Eaton, MA, CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 110 N Main St, Greenville, PA 16125 Phone: 724-589-6287 |
News Archive
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer's disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.
Intermedix Corporation, the leading provider of technology-based business services to emergency healthcare service providers, announced today the acquisition of EMSystems, LLC ("EMSystems"), a leading provider of web-based healthcare information technology solutions in the public health and emergency services markets.
Clinicient Inc., a leader in outpatient rehabilitation business solutions, today announced that Mountain River Physical Therapy, a premier provider of personalized orthopedic, sports and industrial rehabilitation in West Virginia, Pennsylvania, Ohio, Virginia and Florida, selected Clinicient's PracticeInsight cloud based electronic medical record (EMR) and billing software.
There is no danger if your child received the H1N1 vaccine that was recalled by Sanofi Pasteur. That is the information being provided to anyone calling the NJ Poison Control Center's hotline, according to Bruce Ruck, Pharm.D., Director of Drug Information and Professional Education. The public should be reassured that this recall took place because specific lots were found to be slightly weaker than they should have been.
Aerpio Therapeutics, a clinical‐stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory bowel disease, today announced positive data from its Phase 1 trial of AKB-9778 for the treatment of diabetic macular edema.
› Verified 7 days ago